About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Genetically Engineered Immune Cells May Help Fight Relapsed Blood Cancer

by Adeline Dorcas on December 4, 2018 at 2:48 PM
Font : A-A+

Genetically Engineered Immune Cells May Help Fight Relapsed Blood Cancer

Genetically engineered immune cells offer new hope in the fight against relapsed blood cancer, reports a new study.

The University of North Carolina Lineberger Comprehensive Cancer Center researchers reported promising early results from a clinical study of investigational cellular immunotherapy that used a patient's own, genetically engineered immune cells to recognize and fight Hodgkin and non-Hodgkin lymphoma cells.

Advertisement


At the 60th Annual American Society of Hematology Annual Meeting in San Diego, researchers presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker. Data from the phase Ib/II trial showed that the treatment was safe, and it generated "excellent" responses when used after patients were treated with a specific chemotherapy regimen, researchers reported.

"Our results were definitely promising especially given how many patients in the study had progressed on other treatments," said UNC Lineberger's Natalie Grover, MD, an assistant professor in the UNC School of Medicine Division of Hematology/Oncology.
Advertisement

"Hodgkin lymphoma is a generally curable disease, but there is a small percentage of patients who have a bad disease that doesn't respond to therapy. From these early results, this could be a promising option for them."

Cellular immunotherapy involves extracting disease-fighting immune cells - called T-cells - from the patient's blood, and genetically engineering them to recognize the patient's cancer. The researchers use a modified virus to insert DNA into the T-cells, which spurs the T-cells to express a receptor that allows them to recognize and destroy cancer cells. The hybrid T-cells, called chimeric antigen receptor T-cells, or CAR-T cells, are then multiplied and infused back into the patient. UNC Lineberger's first clinical trials used T-cells engineered to recognize tumors expressing the CD30 protein marker.

Researchers presented preliminary data for 24 patients. The majority of patients had Hodgkin lymphoma, a disease affecting white blood cells that are considered one of the most curable cancers. In some patients, however, the disease can progress and become resistant to treatment. Prior to enrolling on the study, most patients had received more than seven treatments, including brentuximab vedotin, which can target the CD30 marker.

In the study, the researchers pre-treated the patients with chemotherapy - a treatment method they called "lymphodepletion" -- prior to an infusion of the CAR T-cells. Of 14 patients who received the chemotherapy regimen of fludarabine and bendamustine, followed by infusion of CAR T-cells, 10 patients, or 71 percent, had a complete response. The median progression-free survival duration for patients in that group was 396 days. Two other patients were in complete response prior to receiving the chemotherapy regimen and weren't included in the results.

Eight patients received an initial pre-treatment regimen of bendamustine only. Three patients, or 37 percent, saw a complete response, although they were responding prior to administration of the new chemotherapy regimen.

"The most important findings were that we identified a lymphodepletion regimen that can be used with these specific CAR T-cells, and make a difference in the outcome for these patients without significant toxicities associated with other cellular immunotherapies," said the study's senior author Barbara Savoldo, MD, PhD, assistant director of the UNC Lineberger Immunotherapy Program and professor of Pediatrics in the Division of Hematology/Oncology at the UNC School of Medicine.

Researchers said their work will be ongoing to try to improve outcomes for the investigational treatment, including through another clinical trial that is designed to evaluate a mechanism for helping to recruit CAR T-cells to tumor sites.

"This study shows this is worth pursuing further, and the next step is to improve on this investigational therapy," Grover said.

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Research News

Good Evening Recovery Leads to Better Work Days
A latest research suggests that the quality of a person's post-work recovery in the evening can impact their mood when they resume work the next day.
Link Between Sleep Apnea and Cognitive Decline
Researchers are working on new strategies and solutions for sleep apnea to ward off a range of health risks including cognitive decline.
Softening Stem Cells Enhances Hair Growth Potential
The scientists discovered that when the stem cells in the hair follicle are made softer, they have a higher chance of growing hair.
Potential New Strategy for Ischemic Stroke Discovered
A combinatorial therapy provided promising beneficial results among people with ischemic stroke.
Is Speech Therapy the Answer to Voice Problems in Parkinson's Disease Patients
In Parkinson's disease patients voice disorders are quite common. A new combination therapy had greater effects on the voice.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Genetically Engineered Immune Cells May Help Fight Relapsed Blood Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests